143691-63-8

Basic information

• Product Name: N-[4-(8-methyl-7-propanoyl-8,9-dihydro-7H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)phenyl]propanamide
• CAS NO: 143691-63-8
• Molecular Formula: C₂₃H₂₅N₃O₄
• Molecular Weight: 407.4623
• Mol File: 143691-63-8.mol

Chemical Properties

• Density: 1.29g/cm³
• Refractive Index: 1.635
• CAS DataBase Reference: N-[4-(8-methyl-7-propanoyl-8,9-dihydro-7H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)phenyl]propanamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-(8-methyl-7-propanoyl-8,9-dihydro-7H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)phenyl]propanamide(143691-63-8)
• EPA Substance Registry System: N-[4-(8-methyl-7-propanoyl-8,9-dihydro-7H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-5-yl)phenyl]propanamide(143691-63-8)

Safety Data

• Hazardous Substances Data: 143691-63-8(Hazardous Substances Data)

Relevant articles and documents

N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic neurodegenerative disorders

The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) R stands for a C1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C1-4 alkylamino, di(C1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group, or by one or more halogen(s); or R is a benzoyl, cyclopropanecarbonyl, C1-5 alkylcarbamoyl or phenylcarbamoyl group; or R is absent when a double bond exists between the N(3) and C(4) atoms; R1 means hydrogen; or R1 is absent when a double bond exists between the N(3) and C(4) atoms; R2 means a C1-3 alkyl group; or R1 and R2 together stand for a methylene group and no double bond is present between the N(3) and C(4) atoms; R3 means hydrogen or a C1-4 alkanoyl group; R4 represents hydrogen; a C1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C1-4 alkylamino, di(C1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group or by one or more halogen(s); as well as a benzoyl, palmitoyl, cyclopropanecarbonyl, C1-5 alkylcarbamoyl or phenylcarbamoyl group; and the dotted lines represent valence bonds optionally being present, with the proviso that no double bond exists between the N(3) and C(4) atoms when both R3 and R4 stand for hydrogen. The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.

N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same

The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) R stands for a C1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C1-4 alkylamino, di(C1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group, or by one or more halogen(s); or R is a benzoyl, cyclopropanecarbonyl, C1-5 alkylcarbamoyl or phenylcarbamoyl group; or R is absent when a double bond exists between the N(3) and C(4) atoms; R1 means hydrogen; or R1 is absent when a double bond exists between the N(3) and C(4) atoms; R2 means a C1-3 alkyl group; or R1 and R2 together stand for a methylene group and no double bond is present between the N(3) and C(4) atoms; R3 means hydrogen or a C1-4 alkanoyl group; R4 represents hydrogen; a C1-6 alkanoyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C1-4 alkylamino, di(C1-4 alkyl)amino, pyrrolidino, phthalimido or phenyl group or by one or more halogen(s); as well as a benzoyl, palmitoyl, cyclopropane-carbonyl, C1-5 alkylcarbamoyl or phenylcarbamoyl group; and the dotted lines represent valence bonds optionally being present, with the proviso that no double bond exists between the N(3) and C(4) atoms when both R3 and R4 stand for hydrogen. The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.

N-acyl-2,3-benzodiazepine derivatives and a method of treating spasms of the skeletal musculature therewith

The invention relates to novel N-acyl-2,3-benzodiezapine derivatives and a method of treating spasms of the skeletal musculature therewith.

N-acyl-2,3-benzodiazepine derivatives, pharmaceutical compositions containing them and process for preparing same

The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I), defined in the specification, a more complete description of the compounds may be found.The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.

N-Acyl-2,3-benzodiazepine derivatives, pharmaceutical compositions containing them and process for preparing same

The invention relates to novel N-acyl-2,3-benzodiezapine derivatives of the general formula (I), their stereoisomers and acid-addition salts, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) Rstands for a C1 6 aliphatic acyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C1 4 alkylamino, di(C1 4 alkyl)amino, pyrrolidino, phthalimido or phenyl group, or by one or more halogen(s); or R is a benzoyl, cyclopropanecarbonyl, C1 5 alkylcarbamoyl or phenylcarbamoyl group; or R is absent when a double bond exists between the N(3) and C(4) atoms; R1means hydrogen; or R1 is absent when a double bond exists between the N(3) and C(4) atoms; R2means a C1 3 alkyl group; or R1 and R2together stand for a methylene group and no double bond is present between the N(3) and C(4) atoms; R3means hydrogen or a C1 4 aliphatic acyl group; R4represents hydrogen; a C1 6 aliphatic acyl group optionally substituted by a methoxy, cyano, carboxyl, amino, C1 4 alkylamino, di(C1 4 alkyl)amino, pyrrolidino, phthalimido or phenyl group or by one or more halogen(s); as well as a benzoyl, palmitoyl, cyclopropanecarbonyl, C1 5 alkylcarbamoyl or phenylcarbamoyl group; and the dotted lines represent valence bonds optionally being present, with the proviso that no double bond exists between the N(3) and C(4) atoms when both R3 and R4 stand for hydrogen. The compounds of the general formula (I) possess valuable central nervous system effects, particularly muscle-relaxant, anticonvulsive and neuroprotective action. Thus, they may be useful for the treatment of various diseases of central nervous system origin.